These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. ALLHAT and beyond. Alderman MH Am J Hypertens; 2003 Jun; 16(6):512-4. PubMed ID: 12799104 [No Abstract] [Full Text] [Related]
27. Drug treatment of hypertension. Conclusion of editorial is somewhat flawed. Hackam DG BMJ; 2003 Apr; 326(7392):764. PubMed ID: 12676853 [No Abstract] [Full Text] [Related]
28. Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Walldius G; Wahlberg G Adv Exp Med Biol; 1985; 183():281-93. PubMed ID: 4036701 [TBL] [Abstract][Full Text] [Related]
29. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Birtcher KK; Bowden C; Ballantyne CM; Huyen M Am J Cardiol; 2000 Feb; 85(3A):30A-35A. PubMed ID: 10695705 [TBL] [Abstract][Full Text] [Related]
30. Low-density lipoprotein cholesterol goal attainment among post myocardial infarction patients on lipid lowering therapy at Siriraj outpatient clinic. Praipaisarnkit K; Wongpraparut N; Pongakasira R J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S147-54. PubMed ID: 24772592 [TBL] [Abstract][Full Text] [Related]
31. [Lipometabolic disorder--cholesterol and triglycerides]. Luley C Clin Res Cardiol; 2006; 95 Suppl 6():VI17-22. PubMed ID: 17013580 [TBL] [Abstract][Full Text] [Related]
32. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Fonarow GC; French WJ; Parsons LS; Sun H; Malmgren JA Circulation; 2001 Jan; 103(1):38-44. PubMed ID: 11136683 [TBL] [Abstract][Full Text] [Related]
33. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Grundy SM Circulation; 2002 Nov; 106(20):2526-9. PubMed ID: 12427645 [No Abstract] [Full Text] [Related]
34. The other side of the bezafibrate infarction prevention trial data. McCormack J; Loewen P Arch Intern Med; 2005 Nov; 165(20):2431-2; author reply 2432. PubMed ID: 16287780 [No Abstract] [Full Text] [Related]
35. Achieving the unachievable: How to optimize lipid-lowering therapy in survivors of acute myocardial infarction. Atar D; Bakken A; Munkhaugen J Kardiol Pol; 2023; 81(4):327-329. PubMed ID: 37144720 [No Abstract] [Full Text] [Related]
36. Specific lipid lowering therapy in the management of diabetes. Durrington PN Postgrad Med J; 1991 Oct; 67(792):947-52. PubMed ID: 1758809 [No Abstract] [Full Text] [Related]
37. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Aronow WS; Ahn C Am J Cardiol; 2002 Jul; 90(2):147-9. PubMed ID: 12106845 [No Abstract] [Full Text] [Related]
38. Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies. Ference BA Cardiol Clin; 2018 May; 36(2):203-211. PubMed ID: 29609749 [TBL] [Abstract][Full Text] [Related]
39. How do prescribing doctors anticipate the effect of statins? Lytsy P; Burell G; Westerling R J Eval Clin Pract; 2011 Jun; 17(3):420-8. PubMed ID: 20545813 [TBL] [Abstract][Full Text] [Related]